As the opioid epidemic continues to pose one of the most critical public health crises in the United States and around the world, the need for innovative, safer treatments has never been more urgent. One company, Nutriband (NASDAQ: NTRB), is aiming to transform how opioid-based therapies are administered and protected against misuse, using its proprietary Aversa technology to set a new standard for transdermal pain and addiction treatments.
Buprenorphine, the next candidate for Aversa, is a medication approved by the U.S. Food and Drug Administration (“FDA”) to treat opioid use disorder (“OUD”) (https://ibn.fm/eQizg). Like NTRB’s Fentanyl patch, it offers an effective and safer alternative to full opioid agonists and has become a cornerstone in medication-assisted treatment (“MAT”) for OUD.
Clinical research supports buprenorphine’s advantages over other opioid treatments. A 2018 study published by the National Institute of Health found that patients with OUD treated with buprenorphine following a nonfatal opioid overdose are associated with significant reductions in opioid related mortality (https://ibn.fm/PYwdo).
NTRB is building on this momentum with their novel transdermal delivery system for buprenorphine, using its patented Aversa abuse-deterrent technology. Rather than relying on traditional oral films or sublingual tablets, Nutriband’s model involves embedding aversive agents into the patch itself, which deters misuse by producing unpleasant effects if the product is tampered with or consumed orally or intravenously. This innovation is especially important given the high rates of misuse associated with even prescribed opioid therapies.
The company’s Aversa pipeline currently includes two main opioid candidates: AVERSA(TM) Fentanyl and AVERSA(TM) Buprenorphine. AVERSA(TM) Fentanyl, Nutriband’s most advanced product, integrates the deterrent system with an FDA-approved fentanyl patch developed by Kindeva Drug Delivery. According to Nutriband, this would be the world’s first abuse-deterrent fentanyl patch, potentially reducing the risk of diversion, misuse and accidental exposure in a category known for both its efficacy and danger.
AVERSA(TM) Buprenorphine, meanwhile, is being positioned as the next step in the company’s growth. In a market update and based off a Health Advances independent report, Nutriband projected potential peak annual sales of $70 million to $130 million for AVERSA(TM) Buprenorphine in the United States alone upon regulatory approval (https://ibn.fm/foAon). The company is also evaluating international commercialization opportunities, supported by its expanding global patent portfolio.
Nutriband’s broader mission is to develop technologies that reduce the potential for abuse and misuse in pain and addiction treatment. The Aversa platform is designed to be applied to a range of transdermal therapies beyond fentanyl and buprenorphine, potentially addressing multiple categories of prescription misuse. The company believes that its approach could help bridge the gap between effective treatment and public health responsibility in the ongoing fight against opioid-related harm.
As regulators, physicians and patients alike seek new tools to battle the opioid epidemic, Nutriband’s efforts could prove pivotal. If successfully commercialized, Aversa-based products may offer a much-needed blend of efficacy, safety and innovation in a space that has long been fraught with challenges.
For more information, visit the company’s website at www.Nutriband.com.
NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Izotropic highlights recurrent challenges in current breast imaging technologies and the need for high-resolution, true…
In the U.S., liver disease claims the lives of at least 52,000 people annually. Globally,…
Sapu003 Phase 1 trial begins: Australian HREC approval validates Oncotelic’s proprietary 20nm nanoparticle technology for…
Brain tumors, such as glioblastoma, are very hard to treat and even surgery isn’t sufficient…
A new study that is being planned by scientists at the University of Calgary, Canada,…
The company has refiled its Abbreviated New Drug Application (“ANDA”) for KETAFREE(TM), a preservative-free IV…